Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBODY 4 extension study of epratuzumab in systemic lupus erythematosus
2010-020859-30Phase 3Completed
- Sponsor
- UCB
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of epratuzumab in systemic lupus erythematosus (SLE), sponsored by UCB. Primary endpoint: Combined response index response at Week 96 and Week 192. Started Nov 2010; status: completed.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2010-020859-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020859-30.